Endologix (ELGX) to Release Quarterly Earnings on Thursday

Endologix (NASDAQ:ELGX) is set to announce its earnings results after the market closes on Thursday, November 1st. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Thursday, August 9th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). The firm had revenue of $44.70 million for the quarter, compared to the consensus estimate of $44.43 million. Endologix had a negative net margin of 40.92% and a negative return on equity of 69.06%. The company’s revenue for the quarter was down 8.0% on a year-over-year basis. During the same period last year, the firm posted ($0.10) earnings per share. On average, analysts expect Endologix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:ELGX opened at $1.22 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.20 and a debt-to-equity ratio of 5.37. Endologix has a twelve month low of $1.09 and a twelve month high of $6.72.



In other Endologix news, CFO Vaseem Mahboob purchased 30,000 shares of the firm’s stock in a transaction dated Thursday, August 16th. The shares were purchased at an average cost of $2.43 per share, with a total value of $72,900.00. Following the completion of the purchase, the chief financial officer now owns 146,812 shares in the company, valued at approximately $356,753.16. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

ELGX has been the topic of several research reports. BTIG Research decreased their price target on shares of Endologix to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 23rd. BidaskClub downgraded shares of Endologix from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Oppenheimer reissued a “hold” rating on shares of Endologix in a research note on Wednesday, October 3rd. BMO Capital Markets reissued a “hold” rating and issued a $4.00 price target (down from $6.50) on shares of Endologix in a research note on Friday, August 10th. Finally, ValuEngine raised shares of Endologix from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $3.86.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

See Also: Hedge Funds – Risk or Reward?

Earnings History for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply